Total Payments
$197,740
2024 Payments
$42,804
Companies
20
Transactions
126
Medicare Patients
2,052
Medicare Billing
$383,358
Payment Breakdown by Category
Consulting$88,539 (44.8%)
Other$49,152 (24.9%)
Research$45,614 (23.1%)
Travel$13,133 (6.6%)
Food & Beverage$1,245 (0.6%)
Education$56.63 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $88,539 | 31 | 44.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $46,589 | 35 | 23.6% |
| Unspecified | $45,614 | 14 | 23.1% |
| Travel and Lodging | $13,133 | 25 | 6.6% |
| Honoraria | $2,325 | 1 | 1.2% |
| Food and Beverage | $1,245 | 15 | 0.6% |
| Compensation for serving as faculty or as a speaker for a medical education program | $237.62 | 1 | 0.1% |
| Education | $56.63 | 4 | 0.0% |
Payments by Type
General
$152,126
112 transactions
Research
$45,614
14 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $50,032 | 41 | $0 (2023) |
| IGI Inc | $31,892 | 7 | $0 (2024) |
| Amgen Inc. | $25,894 | 12 | $0 (2019) |
| Celgene Corporation | $19,806 | 19 | $0 (2020) |
| Takeda Pharmaceuticals U.S.A., Inc. | $14,473 | 7 | $0 (2021) |
| Kite Pharma, Inc. | $12,494 | 9 | $0 (2022) |
| GlaxoSmithKline, LLC. | $7,150 | 5 | $0 (2021) |
| Janssen Biotech, Inc. | $5,079 | 7 | $0 (2022) |
| Alexion Pharmaceuticals, Inc. | $4,680 | 1 | $0 (2024) |
| Alnylam Pharmaceuticals Inc. | $4,128 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $42,804 | 10 | IGI Inc ($31,892) |
| 2023 | $7,293 | 4 | E.R. Squibb & Sons, L.L.C. ($3,855) |
| 2022 | $12,837 | 8 | Kite Pharma, Inc. ($6,294) |
| 2021 | $11,912 | 6 | Takeda Pharmaceuticals U.S.A., Inc. ($3,970) |
| 2020 | $25,019 | 12 | PFIZER INC. ($6,000) |
| 2019 | $48,202 | 28 | PFIZER INC. ($18,360) |
| 2018 | $29,389 | 36 | PFIZER INC. ($11,900) |
| 2017 | $20,284 | 22 | PFIZER INC. ($10,242) |
All Payment Transactions
126 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/24/2024 | JAZZ PHARMACEUTICALS INC. | RYLAZE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,532.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/06/2024 | Alexion Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $4,680.00 | General |
| 10/09/2024 | IGI Inc | — | — | Cash or cash equivalent | $14,400.00 | Research |
| Study: ISB2001-101 | ||||||
| 10/09/2024 | IGI Inc | — | — | Cash or cash equivalent | $7,168.00 | Research |
| Study: ISB2001-101 | ||||||
| 10/09/2024 | IGI Inc | — | — | Cash or cash equivalent | $3,456.00 | Research |
| Study: ISB2001-101 | ||||||
| 10/09/2024 | IGI Inc | — | — | Cash or cash equivalent | $3,200.00 | Research |
| Study: ISB2001-101 | ||||||
| 10/09/2024 | IGI Inc | — | — | Cash or cash equivalent | $1,689.60 | Research |
| Study: ISB2001-101 | ||||||
| 10/09/2024 | IGI Inc | — | — | Cash or cash equivalent | $698.22 | Research |
| Study: ISB2001-101 | ||||||
| 04/17/2024 | IGI Inc | — | — | Cash or cash equivalent | $1,280.00 | Research |
| Study: ISB2001-101 | ||||||
| 01/16/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $2,700.00 | General |
| 12/10/2023 | PFIZER INC. | BESPONSA (Biological) | — | In-kind items and services | $3,200.00 | Research |
| Study: INOTUZUMAB OZOGAMICIN CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 02/14/2023 | AstraZeneca Pharmaceuticals LP | — | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $237.62 | General |
| 02/13/2023 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,076.00 | General |
| 01/25/2023 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $1,779.00 | General |
| 12/01/2022 | Janssen Biotech, Inc. | TECVAYLI (Biological) | Consulting Fee | Cash or cash equivalent | $1,262.50 | General |
| Category: Oncology | ||||||
| 10/28/2022 | Kite Pharma, Inc. | Tecartus (Drug) | Consulting Fee | Cash or cash equivalent | $5,000.00 | General |
| Category: CELLT | ||||||
| 10/07/2022 | Kite Pharma, Inc. | Tecartus (Drug) | Travel and Lodging | In-kind items and services | $885.21 | General |
| Category: CELLT | ||||||
| 10/07/2022 | Kite Pharma, Inc. | Tecartus (Drug) | Travel and Lodging | In-kind items and services | $239.00 | General |
| Category: CELLT | ||||||
| 10/07/2022 | Kite Pharma, Inc. | Tecartus (Drug) | Travel and Lodging | In-kind items and services | $169.86 | General |
| Category: CELLT | ||||||
| 09/09/2022 | Legend Biotech USA Inc. | CARVYKTI (Biological) | Consulting Fee | Cash or cash equivalent | $2,550.00 | General |
| Category: Oncology | ||||||
| 05/18/2022 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Consulting Fee | Cash or cash equivalent | $2,400.00 | General |
| Category: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | ||||||
| 01/10/2022 | PFIZER INC. | BESPONSA (Biological) | — | In-kind items and services | $330.00 | Research |
| Study: INOTUZUMAB OZOGAMICIN CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 11/18/2021 | Takeda Pharmaceuticals U.S.A., Inc. | ICLUSIG (Drug) | Education | In-kind items and services | $9.99 | General |
| Category: ONCOLOGY | ||||||
| 10/06/2021 | Janssen Scientific Affairs, LLC | DARZALEX (Drug) | Consulting Fee | Cash or cash equivalent | $1,767.50 | General |
| Category: Oncology | ||||||
| 07/14/2021 | Janssen Biotech, Inc. | DARZALEX (Biological) | Consulting Fee | Cash or cash equivalent | $2,525.00 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ISB2001-101 | IGI Inc | $31,892 | 7 |
| INOTUZUMAB OZOGAMICIN CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $9,530 | 5 |
| CRB-401 A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma (CRB-401) | Celgene Corporation | $2,866 | 1 |
| CRB-401 - CRB-401 A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma | Celgene Corporation | $1,326 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 573 | 1,077 | $630,586 | $117,811 |
| 2022 | 8 | 493 | 869 | $513,923 | $91,742 |
| 2021 | 11 | 567 | 965 | $528,456 | $101,150 |
| 2020 | 10 | 419 | 760 | $361,147 | $72,654 |
Total Patients
2,052
Total Services
3,671
Medicare Billing
$383,358
Procedure Codes
39
All Medicare Procedures & Services
39 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 166 | 332 | $266,829 | $42,843 | 16.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 62 | 304 | $112,826 | $32,725 | 29.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 156 | 223 | $132,668 | $18,375 | 13.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 40 | 47 | $35,579 | $7,517 | 21.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 40 | 40 | $32,959 | $6,217 | 18.9% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 33 | 38 | $16,644 | $3,963 | 23.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 27 | 42 | $11,340 | $3,064 | 27.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 37 | 39 | $18,036 | $2,196 | 12.2% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 12 | 12 | $3,705 | $910.92 | 24.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 149 | 291 | $233,982 | $37,748 | 16.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 52 | 227 | $83,536 | $20,685 | 24.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 134 | 170 | $100,700 | $13,796 | 13.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 38 | 38 | $32,902 | $6,402 | 19.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 34 | 35 | $24,416 | $6,082 | 24.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 50 | 61 | $22,921 | $3,207 | 14.0% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 22 | 23 | $9,584 | $2,254 | 23.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 14 | 24 | $5,882 | $1,568 | 26.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 127 | 232 | $186,942 | $29,975 | 16.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 64 | 268 | $98,624 | $25,285 | 25.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 122 | 163 | $94,456 | $13,824 | 14.6% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 54 | 54 | $48,216 | $9,158 | 19.0% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 36 | 42 | $27,636 | $7,653 | 27.7% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 44 | 50 | $20,150 | $4,903 | 24.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 55 | 60 | $25,080 | $3,457 | 13.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 25 | 53 | $12,932 | $3,452 | 26.7% |
About Dr. Michaela Liedtke, MD
Dr. Michaela Liedtke, MD is a Hematology healthcare provider based in Stanford, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/13/2007. The National Provider Identifier (NPI) number assigned to this provider is 1609918556.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michaela Liedtke, MD has received a total of $197,740 in payments from pharmaceutical and medical device companies, with $42,804 received in 2024. These payments were reported across 126 transactions from 20 companies. The most common payment nature is "Consulting Fee" ($88,539).
As a Medicare-enrolled provider, Liedtke has provided services to 2,052 Medicare beneficiaries, totaling 3,671 services with total Medicare billing of $383,358. Data is available for 4 years (2020–2023), covering 39 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology
- Location Stanford, CA
- Active Since 02/13/2007
- Last Updated 04/12/2024
- Taxonomy Code 207RH0000X
- Entity Type Individual
- NPI Number 1609918556
Products in Payments
- BESPONSA (Biological) $35,090
- Kyprolis (Biological) $22,380
- NINLARO (Drug) $10,503
- Tecartus (Drug) $10,394
- BB-2121 (Drug) $7,356
- BESPONSA (Drug) $5,790
- Revlimid (Drug) $5,197
- OXLUMO (Drug) $4,128
- EXKIVITY (Drug) $3,960
- DARZALEX (Biological) $3,817
- BLENREP (Biological) $3,575
- RYLAZE (Drug) $3,532
- Parsabiv (Biological) $3,500
- CARVYKTI (Biological) $2,550
- SARCLISA (Biological) $2,517
- clonoSEQ (Device) $2,400
- XPOVIO (Drug) $2,325
- DARZALEX (Drug) $1,768
- TECVAYLI (Biological) $1,263
- MYLOTARG (Drug) $803.74
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology Doctors in Stanford
Saad Munib Ahmed Khan, Md, MD
Hematology — Payments: $315,298
Hematology $315,298
Surbhi Sidana, M.d, M.D
Hematology — Payments: $111,114
Hematology $111,114
Robert Negrin, M.d, M.D
Hematology — Payments: $56,100
Hematology $56,100
Ravindra Majeti, M.d, M.D
Hematology — Payments: $54,202
Hematology $54,202
Robert Ohgami, M.d., Ph.d, M.D., PH.D
Hematology — Payments: $16,248
Hematology $16,248
Neel Gupta, Md, MD
Hematology — Payments: $10,266
Hematology $10,266